A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure

Inclusion criteria

• 1) Age from 18 to 80 years, both genders are eligible ;
• 2) Clinically judged to be suitable for CABG treatment due to chronic ischemic cardiomyopathy;
• 3) LVEF (left ventricular ejection fraction) is ≤ 40% as indicated by echocardiography (modified Simpson method) or cardiac magnetic resonance (CMR);
• 4) NYHA (New York Heart Association) cardiac function classification of grade II-IV;
• 5) Patients or their legal guardians agreed to participate in this trial and signed the informed consent form.

Major exclusion Criteria:

• 1) Severe left ventricular dysfunction, with LVEF ≤ 20% (based on the UCG or CMR examination results during the screening period);
• 2) Non-ischemic chronic left heart dysfunction, including but not limited to acute left heart dysfunction, dilated cardiomyopathy, severe right heart dysfunction (such as bilateral lower extremity edema accompanied by jugular vein distension, liver enlargement, etc.) or severe pulmonary hypertension (PASP > 70 mmHg);
• 3) Clinically determined that other surgical procedures need to be performed simultaneously during CABG surgery, including but not limited to congenital heart disease requiring concurrent surgical intervention, heart valve disease, ventricular aneurysm, ventricular septal perforation, papillary muscle dysfunction, aortic dissection, intracardiac mass, thrombus or neoplasm；
• 4) Acute ST-segment elevation myocardial infarction or stroke event within 1 month before enrollment；
• 5) Uncontrolled malignant arrhythmia;
• 6)have undergone or are awaiting heart transplantation or implantation of a left ventricular assist device (LVAD).